India is home to several reputable
Gefitinib tablet manufacturers, known for producing high-quality and cost-effective versions of this targeted cancer therapy. Gefitinib is used primarily in the treatment of non-small cell lung cancer, offering a tailored approach to patients with specific genetic mutations. Indian manufacturers, such as Cipla, Natco Pharma, and Dr. Reddy's Laboratories, have made Gefitinib more accessible globally by offering affordable generic alternatives. These companies ensure strict compliance with international regulatory standards, enabling patients worldwide to benefit from life-saving cancer treatments at a fraction of the cost of branded versions.